Dr. Nakayama on Using Precision Medicine With Mirvetuximab Soravtansine in Ovarian Cancer

John Nakayama, MD, assistant professor, Department of Reproductive Biology, School of Medicine, Case Western Reserve University, member, Cancer Prevention Control and Population Research Program, Case Comprehensive Cancer Center, attending physician, Department of OB/GYN-Gynecological Oncology, University Hospitals Cleveland Medical Center, and attending physician, Gynecological Cancer Care Team, University Hospitals Seidman Cancer Center, discusses the potential utility of precision medicine with mirvetuximab soravtansine in ovarian cancer.

Mirvetuximab soravtansine is an antibody-drug conjugate that has demonstrated efficacy in women with advanced, high-grade, platinum-resistant epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor–α (FRα) expression.

The activity of the agent in this patient population suggests that the future of ovarian cancer treatment will not be limited to standard cytotoxic chemotherapy, says Nakayama. Rather than utilizing a one-size-fits-all approach, the field will likely push toward a precision medicine approach for patients, Nakayama explains.

For example, patients could undergo genetic testing to determine BRCA status and whether treatment with a PARP inhibitor is warranted, says Nakayama. Additional testing to determine FRα expression could then inform whether a patient is eligible for mirvetuximab soravtansine, concludes Nakayama.